Keyphrases
Solid Dispersion
100%
Physical Stability
87%
Critically Ill Patients
87%
Imipenem
87%
Solid-state Form
79%
Amorphous Form
76%
Polyol
54%
Solubility Enhancement
54%
Amorphous Solid Dispersion
54%
Therapeutic Agents
54%
Sinusitis
51%
Influenza
51%
Active Pharmaceutical Ingredients
51%
South Africa
51%
Therapeutic Drug Monitoring
51%
Amorphous Solids
49%
Aqueous Solubility
49%
Nanoengineering
43%
Engineering Approach
43%
Crystal Engineering
43%
Cross-linked Gel
43%
Crystalline Formulation
43%
Crystallization Kinetics
43%
Sulfadoxine
43%
Zopiclone
43%
Stability Kinetics
43%
Quality by Design
43%
In-process
43%
Robust Stability
43%
Simultaneous Detection
43%
Bulk Material
43%
Material Formulation
43%
Stability Indicating HPLC
43%
Dissolution Enhancement
43%
Thermodynamic Study
43%
Roxithromycin
43%
Morphological Study
43%
COVID-19 Guidelines
43%
COVID-19
43%
Pharmaceutical Products
43%
Drug Delivery
43%
Cancer Treatment
43%
Pharmaceutical Formulations
43%
Nervous System Diseases
43%
Dolutegravir
43%
Tenofovir Disoproxil Fumarate
43%
Neoplastic Disease
43%
Kinetic Study
43%
Lamivudine
43%
Preparation Method
43%
Pharmacology, Toxicology and Pharmaceutical Science
Imipenem
87%
Disease
74%
Dosage Forms
61%
Sinusitis
58%
Polyol
58%
Amorphous Solid Dispersion
58%
High Performance Liquid Chromatography
53%
Therapeutic Drug Monitoring
49%
Crystallization Kinetics
43%
Central Nervous System Drug
43%
Sulfadoxine
43%
Controlled Drug Release
43%
Central Nervous System Disease
43%
Crystal Engineering
43%
Drug Stability
43%
Roxithromycin
43%
Coronavirinae
43%
Dolutegravir
43%
Tenofovir Disoproxil
43%
Excipient
43%
Drug Delivery System
43%
Carbohydrates
43%
Neoplasm
43%
Pollen Allergy
43%
Lamivudine
43%
Reverse Phase High Performance Liquid Chromatography
43%
Malignant Neoplasm
43%
Maltitol
43%
Zopiclone
43%
Isoniazid
36%
Scanning Electron Microscopy
35%
Differential Scanning Calorimetry
28%
Trough Level
25%
Bioavailability
25%
Anticarcinogen
21%
Antibiotics
21%
Allergic Rhinitis
20%
Cilastatin
18%
Influenza
16%
Methanol
14%
Mortality Rate
14%
Drug Solubility
14%
Stability of Solid
14%
Vaccine Development
14%
Angiotensin Receptor Antagonist
14%
Communicable Disease
14%
Non-Steroidal Anti-Inflammatory Drug
14%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Incubation Time
14%
Povidone
13%